CMC Biologics, Inc. and Zymeworks Inc. have entered into a Master Services Agreement for the process development, formulation development, and cGMP clinical manufacture of a recombinant human IgG1 bi-specific (heterodimeric) antibody.
"Being selected by Zymeworks, who are known for developing best-in-class and highly effective protein therapeutics, is a natural fit for us and validates our technical excellence and partnering philosophy," said Gustavo Mahler, Ph.D., global chief operations officer of CMC Biologics. "Through this agreement, Zymeworks and CMC Biologics will work together to advance the next frontier of bi-specific antibody development platforms and bring novel therapies to patients in need."
"As we advance our lead Azymetric oncology program and first therapeutic built on our proprietary ZymeCAD platform, choosing a contract partner with a track record of success in development and manufacturing is critical," said Ali Tehrani, Ph.D., president and chief executive officer of Zymeworks. "Our collaboration with CMC Biologics helps position us to move our oncology program into clinical trials for the treatment of breast cancer and other solid tumors, as well as subsequent therapeutic candidates targeted towards hematological cancers such as leukemia and lymphoma."